Andrew Arther, MD
Urology · Kansas City, KSNPI 1134355167
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,245 of the $3,677 with a category attached, or 88.2%. It is spread thinly across 40 manufacturers, the largest accounting for just 12.9% — the pattern of someone who eats at a lot of different presentations.
Across 148 payments — averaging $24.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$476
- Axonics, Inc.$448
- Astellas Pharma US Inc$352
- Boston Scientific$203
- Palette Life Sciences, Inc.$184
- Calyxo, Inc.$181
- plus $2K from 34 others
What the payments were for
- Food & beverage$3,24588%
- Education$43312%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 33 | $476 |
| Axonics, Inc. | 14 | $448 |
| Astellas Pharma US Inc | 12 | $352 |
| Boston Scientific | 6 | $203 |
| Palette Life Sciences, Inc. | 1 | $184 |
| Calyxo, Inc. | 2 | $181 |
| Uromedica, Incorporated | 1 | $175 |
| Medtronic(2 entities) | 8 | $142 |
| Merck | 7 | $128 |
| Verity Pharmaceuticals Inc. | 7 | $123 |
| Sumitomo Pharma America, Inc. | 6 | $120 |
| Pfizer | 8 | $102 |
| Seagen Inc. | 1 | $100 |
| Laborie Medical Technologies Corp. | 1 | $92 |
| Tolmar, Inc. | 5 | $92 |
| Endo Pharmaceuticals Inc. | 5 | $73 |
| Dornier Medtech America, Inc | 1 | $62 |
| Valencia Technologies Corporation | 1 | $57 |
| Johnson & Johnson | 3 | $56 |
| Urogen Pharma, Inc. | 3 | $52 |
| Bayer | 3 | $44 |
| AstraZeneca | 1 | $35 |
| Coloplast | 2 | $33 |
| Procept Biorobotics Corporation | 1 | $29 |
| Progenics Pharmaceuticals, Inc. | 1 | $29 |
| Conmed Corporation | 1 | $29 |
| Novartis | 1 | $25 |
| Endo USA, Inc. | 1 | $23 |
| KARL Storz Endoscopy-america | 1 | $23 |
| Dendreon Pharmaceuticals LLC | 1 | $22 |
| Amgen | 1 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $20 |
| Ferring Pharmaceuticals Inc. | 1 | $20 |
| Pacira Pharmaceuticals Incorporated | 1 | $19 |
| Cook Medical LLC | 1 | $17 |
| Tolmar Pharmaceuticals, Inc. | 1 | $16 |
| Vertex | 1 | $16 |
| Clinigen, Inc. | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
| 180 Medical, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ProACT$175
- CVAC Aspiration System$156
- Axonics$119
- REZUM$113
How this compares
$3,677 in reported general payments places this provider in the 60th percentile of 111 urology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 277 | $175,783 |
| GemtesaVibegron | 153 | $83,851 |
| JatenzoTestosterone Undecanoate | 13 | $13,549 |
| Tamsulosin Hcl | 586 | $7,227 |
| Solifenacin Succinate | 109 | $5,801 |
| NitrofurantoinNitrofurantoin Macrocrystal | 132 | $5,064 |
| Methenamine Hippurate | 52 | $3,074 |
| Desmopressin Acetate | 89 | $3,006 |
| Potassium Citrate ErPotassium Citrate | 33 | $2,763 |
| RenacidinCitric Ac/Gluconolact/Mag Carb | 14 | $2,736 |
| Silodosin | 33 | $2,107 |
| Finasteride | 201 | $2,078 |
| Oxybutynin Chloride ErOxybutynin Chloride | 84 | $1,575 |
| Testosterone Cypionate | 37 | $1,535 |
| Tolterodine Tartrate ErTolterodine Tartrate | 14 | $1,254 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $352 | $175,783277 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $120 | $83,851153 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 111 urology providers in Kansas.
Other urology in Kansas City
- Wilson MolinaKansas City$239K
- Bristol WhilesKansas City$163K
- Jeffrey HolzbeierleinKansas City$78K
- Ahmad El-ArabiKansas City$55K
- David DucheneKansas City$33K
- Joshua BroghammerKansas City$24K
- William ParkerKansas City$20K
- John TaylorKansas City$9K
- Casey KowalikKansas City$8K
- Richard FantusKansas City$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.